BioInvent International (BINV) investor relations material

Introduction and agenda

• Event featured leading experts discussing advances in hematology, focusing on follicular lymphoma and CTCL, with presentations on clinical assets BI-1206 and BI-1808, followed by Q&A sessions.

• Agenda included overviews of treatment landscapes, unmet needs, clinical updates, commercial perspectives, and future development plans.

• KOL lunch briefing held in conjunction with EHA 2026 Congress, presenting new clinical data on BI-1808 in advanced CTCL, both as monotherapy and in combination with pembrolizumab.

KOL background and credentials

• Guilherme Perini, São Paulo Hospital, Brazil, specializes in lymphoma treatment and clinical trials.

• Stefan Barta, Abramson Cancer Center, UPenn, leads the T-cell lymphoma program and focuses on immunotherapy and biomarkers.

• Presentation by Stefan K. Barta, MD, MS, Associate Professor of Medicine (Hematology-Oncology) and Director of the T-Cell Lymphoma Program at the Abramson Cancer Center, University of Pennsylvania.

Market insights and analysis

• Follicular lymphoma treatment is shifting toward chemo-free regimens, with new agents and combinations improving outcomes but raising toxicity and access concerns.

• CTCL remains a rare, chronic disease with high unmet need for durable, tolerable therapies; current options have significant limitations and side effects.

• Advanced CTCL has poor long-term outcomes and limited durable responses, highlighting significant unmet medical need.

• Market research indicates strong commercial opportunities for both BI-1206 and BI-1808, with recurring revenue potential due to chronic, relapsing nature of diseases.

• BI-1808 holds FDA Fast Track and Orphan Drug designations, and positive EMA opinion, supporting accelerated approval pathways.